More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says

Eli Lilly said more than 20,000 people have started its GLP-1 pill Foundayo in the first few weeks after FDA approval, with over 1,000 new starts per day and more than 80% of users new to GLP-1s. CEO Dave Ricks said demand is organic and will build over quarters, not days, while Lilly’s first-quarter results also beat expectations and Mounjaro and Zepbound sales rose 125% and 80%, respectively. Lilly held a 60.1% share of the U.S. obesity and diabetes drug market in Q1 versus 39.4% for Novo Nordisk.

Analysis

The key read-through is not just that the launch is healthy, but that Lilly is showing an unusually strong conversion funnel into an entirely new category of patients. That implies the company is attacking the market from the demand side, not merely cannibalizing existing GLP-1 users, which is structurally more durable and should support a longer revenue runway than investors typically assume in week-one launch parsing.

For Novo, this is a share-retention problem disguised as a brand problem. If Lilly can keep new-to-GLP-1 users flowing at even a fraction of the current pace, the pressure on Novo’s future mix worsens because the market is increasingly being won by first-presentation physician choice rather than legacy brand loyalty. The second-order effect is that payers and employers will likely intensify formulary pressure and rebate negotiations across the class, which can compress net pricing even for the leader.

The biggest near-term risk to the bullish interpretation is not demand, but execution cadence: oral GLP-1s need sustained persistence data, tolerability confirmation, and broader prescriber familiarity over the next 2-3 quarters. If early starters drop off or if refill behavior lags, the launch could look better in gross adds than in durable treated patients. That said, the market seems underappreciating how much easier it is to expand total GLP-1 penetration with an oral format than to simply steal share from existing injectable users.

Consensus is probably over-fixating on weekly scripts as a trading signal and underestimating the strategic option value of a second successful oral entry. The more important implication is that Lilly is building a multi-format franchise that can defend against future category pricing compression by keeping patients inside its ecosystem longer. Novo’s relative underperformance risk is therefore less about one product and more about ceding the default-choice position in obesity treatment.

Key Decisions for Investors

• Maintain/trim short NVO exposure over the next 4-8 weeks; use rallies to add, with a stop if weekly launch data show sustained acceleration beyond current run-rate
• Go long LLY vs short NVO as a 3-6 month pair trade to express share-gain and brand-deflection risk; target multiple expansion on LLY and compression on NVO if prescription momentum persists
• Buy near-dated LLY call spreads into the next monthly prescription update; the setup favors upside convexity because the market is still discounting durable persistence rather than just initial starts
• For lower-risk expression, initiate a healthcare basket pair: long large-cap obesity leaders vs short a basket of payer-sensitive pharma names, anticipating rebate pressure and class-level margin compression over 2-4 quarters
• Set a tactical alert on NVO if U.S. share trends continue to drift lower for 6-8 weeks; that is the point where consensus may have to re-rate the competitive moat, making a larger short more attractive